Synlogic (Synlogic) ROCE % : -103.56% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Synlogic ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Synlogic's annualized ROCE % for the quarter that ended in Dec. 2023 was -103.56%.

Synlogic ROCE % Historical Data

The historical data trend for Synlogic's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synlogic ROCE % Chart

Synlogic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-32.95

-37.54

-40.35

-50.22

-74.43

Synlogic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-62.02	-68.49	-78.45	-76.21	-103.56

Synlogic ROCE % Calculation

Synlogic's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-57.267	/	( ( (110.865 - 12.122)	+	(75.55 - 20.404) )	/ 2 )
	=	-57.267	/	( (98.743	+	55.146)	/ 2 )
	=	-57.267	/	76.9445
	=	-74.43 %

Synlogic's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-58.128	/	( ( (66.254 - 9.144)	+	(75.55 - 20.404) )	/ 2 )
	=	-58.128	/	( ( 57.11	+	55.146 )	/ 2 )
	=	-58.128	/	56.128
	=	-103.56 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Synlogic (NAS:SYBX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Synlogic ROCE % Related Terms

Thank you for viewing the detailed overview of Synlogic's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Synlogic (Synlogic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synlogic Inc (NAS:SYBX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0A8U:UK

Address

301 Binney Street, Suite 402, Cambridge, MA, USA, 02142

Website

https://www.synlogictx.com

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects.

Executives

Michael Vangsted Jensen	officer: Chief Financial Officer	301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Aoife Brennan	officer: Chief Medical Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Antoine Awad	officer: Chief Operating Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Lisa Kelly-croswell	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Michael F. Burgess	director	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Richard P Shea	director	C/O MOMENTA PHARMACEUTICALS, INC., 43 MOULTON STREET, CAMBRIDGE MA 02138
Gregg Beloff	officer: See Remarks	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Richard J. Riese	officer: Chief Medical Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE MA 02142
Ginkgo Bioworks, Inc.	10 percent owner	27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Scott Eric Plevy	officer: Chief Scientific Officer	301 BINNEY STREET, #402, C/O SYNLOGIC, INC., CAMBRIDGE MA 02142
Paul Francis Miller	officer: Chief Scientific Officer	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Patricia N. Hurter	director	C/O SYNLOGIC, INC., 301 BINNEY ST., SUITE 402, CAMBRIDGE MA 02142
Andrew Gengos	officer: See Remarks	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Todd Shegog	officer: See Remarks	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139